Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of FR104 in de novo kidney transplant recipients
2024-516577-76-00Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Aug 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of FR104 in kidney transplant immunosuppression, sponsored by CHU de Nantes. Primary endpoints: Safety and tolerability of FR104, Pharmacokinetics of FR104 and 2 more. Started Aug 2024; status: completed.
02
Drugs
FR104
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2024-516577-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516577-76-00.